Abstract 5519
Background
The elderly (above 65 years) have become the leading population of our society. Their multitude of healthcare chronic problems demands palliative care and therefore Palliative Care problems and needs (PCPN) assessment.
Methods
A quantitative study using structured questionnaires [PNPC, Mini – Mental State Examination (MMSE), demographic and clinical characteristics] was conducted through December 2018 – February 2019, at internal medicine wards of a public general hospital. Patients with MMSE<24, at the end of life and with recent surgery were excluded. A translated in Hellenic language short-form version of PCPN used assessing Palliative Care Problems and Need for Professional Care. The PCPN is a 33 items 3-point Likert type scale that covers 8 domains: Activities of daily living (ADL/IADL), Physical symptoms (PS), Autonomy (A), Social (SI), Psychological (PI), Spiritual issues (Sp), Financial problems (FP) and Need for information (NI). The level of statistical significance was set at 0.05.
Results
Sample consisted of 150 patients (51% men) with mean age 75.6 years old (SD = 10.1). The cancer diagnosis was 40% mostly colon cancer (38%) and for non-cancer patients hypertension (62.2%). No statistical differences were found between cancer and non cancer patients for the demographic and clinical characteristics (p > 0.05). The mean MMSE scare was 27.2 (SD = 2) in patients with cancer and 27.6 (SD = 1.9) in patients with no cancer (p = 0.313). Significantly greater scores were found on the ADL/IADL (p=.012 - p=.001), A (p=.050 - p=.002), SI (p=.007 - p=.004) and Sp (p=.014 - p=.001) in the cancer group for both problems and needs for care. Additionally, the cancer patients reported statistically significant higher need for professional care for FP (p=.022). No statistically significant differences were found for PS, PI and NI (p>.050).
Conclusions
Elderly hospitalized cancer patients have more palliative care problems and needs for care at daily living, social, spiritual and financial issues than those with no cancer. Hence, nurses should focus on meeting these needs, based on the principles of PC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract